<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Daya Banyu Bening</style></author><author><style face="normal" font="default" size="100%">Reni Prastyani</style></author><author><style face="normal" font="default" size="100%">Nurwasis</style></author><author><style face="normal" font="default" size="100%">Evelyn Komaratih</style></author><author><style face="normal" font="default" size="100%">Ismi Zuhria</style></author><author><style face="normal" font="default" size="100%">Hari Basuki Notobroto</style></author><author><style face="normal" font="default" size="100%">Dyah Fauziah</style></author><author><style face="normal" font="default" size="100%">Chrismawan Ardianto</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Expressions of Matrix Metalloproteinase-3 and Tissue Inhibitor Metalloproteinase-1 in Corneal Tissue Post Alkali Burn Treated with Topical Medroxyprogesterone Acetate and Doxycycline</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Corneal alkali burn</style></keyword><keyword><style  face="normal" font="default" size="100%">Doxycycline.</style></keyword><keyword><style  face="normal" font="default" size="100%">Medroxyprogesterone acetate</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2023</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">15</style></volume><pages><style face="normal" font="default" size="100%">553-557</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Purpose: &lt;/strong&gt;This study aims to investigate the effects of topical Medroxyprogesterone acetate (MPA) and Doxycycline in inhibiting the expression of MMP-3 and TIMP-1 in ocular alkali burn models in animals. &lt;strong&gt;Methods: &lt;/strong&gt;A total of 18 New Zealand Rabbits were divided into 3 groups based on their post-alkali-burn treatment: PBS (G1/ control group), topical Doxycycline 1mg/ml (G2), and topical MPA 1% (G3). Alkali burn models were made by exposing 1N NaOH solution to the central cornea for 30 seconds. MMP-3 and TIMP-1 expression were evaluated using immunohistochemistry after 14 days of treatment. &lt;strong&gt;Results:&lt;/strong&gt;&lt;strong&gt; &lt;/strong&gt;Statistically significant differences in the mean MMP-3 expression were found between the three groups (p=0.010). There was a significant difference in MMP-3 expression between the control group with MPA (p=0.017) and Doxycycline (p=0.028) but was not found between the MPA and Doxycycline groups (p=1,000). The mean differences in TIMP-1 expression between the three treatment groups were statistically significant (p=0.005), with a significant difference between the control group with Doxycycline (p=0.022) and MPA (p=0.007). There was no significant difference in TIMP-1 expression between the Doxycycline and MPA groups (P=1,000). &lt;strong&gt;Conclusion: &lt;/strong&gt;This study indicated that topical administration of Doxycycline or MPA in ocular alkali burn reduces the expression of MMP-3 and TIMP-1.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Original Article </style></work-type><section><style face="normal" font="default" size="100%">553</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p&gt;&lt;strong&gt;Daya Banyu Bening&lt;sup&gt;1&lt;/sup&gt;, Reni Prastyani&lt;sup&gt;1,*&lt;/sup&gt;, Nurwasis&lt;sup&gt;1&lt;/sup&gt;, Evelyn Komaratih&lt;sup&gt;1&lt;/sup&gt;, Ismi Zuhria&lt;sup&gt;1&lt;/sup&gt;, Hari Basuki Notobroto&lt;sup&gt;2&lt;/sup&gt;, Dyah Fauziah&lt;sup&gt;3&lt;/sup&gt;, Chrismawan Ardianto&lt;sup&gt;4&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;1&lt;/sup&gt;Department of Ophthalmology, Dr. Soetomo General Academic Hospital / Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Biostatistics and Population, Faculty of Public Health, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;3&lt;/sup&gt;Department of Anatomical Pathology, Faculty of Medicine, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;

&lt;p&gt;&lt;sup&gt;4&lt;/sup&gt;Department of Clinical Pharmacy, Faculty of Pharmacy, Airlangga University, Surabaya, INDONESIA.&lt;/p&gt;
</style></auth-address></record><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Judya Sukmana</style></author><author><style face="normal" font="default" size="100%">Widjiati</style></author><author><style face="normal" font="default" size="100%">Siswandono</style></author><author><style face="normal" font="default" size="100%">I Ketut Sudiana</style></author><author><style face="normal" font="default" size="100%">Hari Basuki Notobroto</style></author><author><style face="normal" font="default" size="100%">Iswinarno Doso Saputro</style></author><author><style face="normal" font="default" size="100%">Yoes Prijatna Dachlan</style></author><author><style face="normal" font="default" size="100%">Endang Joewarini</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Leaf Effect of C. Trifolia L. as Nf-B and Tnf-Α Inhibitor Compounds with In Silico Method</style></title><secondary-title><style face="normal" font="default" size="100%">Pharmacognosy Journal</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">C. trifolia L</style></keyword><keyword><style  face="normal" font="default" size="100%">H. Pylori</style></keyword><keyword><style  face="normal" font="default" size="100%">in silico</style></keyword><keyword><style  face="normal" font="default" size="100%">NFkB</style></keyword><keyword><style  face="normal" font="default" size="100%">TNF-α</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">August 2022</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">14</style></volume><pages><style face="normal" font="default" size="100%">407-415</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Infection &lt;em&gt;H. pylori &lt;/em&gt;causes inflammation through various pathways to induce proinflammatory cytokines such as IL-1, IL-6, IL-8, and TNF-α. The transcription factor NF-kB is a crucial regulator of the immune response and inflammation and regulates many cellular processes that are important in carcinogenesis, including transformation, proliferation, angiogenesis, and metastasis. Antiinflammatory plant&lt;em&gt; C. trifolia &lt;/em&gt;L was shown to inhibit the activity of NF-B and several pro-inflammatory cytokine mediators. This study proved that the active compound from the plant's leaves,&lt;em&gt; C. trifolia &lt;/em&gt;L has potential as an inhibitor of NF-B and TNF-α. &lt;strong&gt;Method:&lt;/strong&gt; This study used a docking method with a grid box mimicking the bond between the receptor and the inhibitor control complex. &lt;strong&gt;Results: &lt;/strong&gt;The bioactivity of &lt;em&gt;Cayratria trifolia &lt;/em&gt;compounds as anti-inflammatory was shown in the inflammation parameters used, namely Interleukin 10 agonist, Interleukin agonist, Interleukin antagonist, Interleukin 6 antagonist, Interleukin 4 antagonist, Interleukin 2 agonist, Interleukin 1 antagonist, Interleukin 1b antagonist, Interleukin 10 antagonist, Interleukin 12 agonist, and Interleukin 1a antagonist. Interleukin 2 agonists showed the highest activity of all compounds. Piceid compounds showed high anti-inflammatory activity with interleukin 10 agonists, interleukin agonists, interleukin 6 antagonists, and interleukin 2 agonists. The compounds stilbenes, piceid, resveratrol, cyclopentadecane, and hentriacontane showed potency higher interleukin-6 inhibition than the other 22 compounds. These five compounds were continued for molecular docking analysis. The low bond energy is correlated with the number of bonds and the variety of interactions. The higher the number of bonds and the type of interaction, the lower the bond energy. The lower the bond energy, the stronger the interaction between the ligand and protein. &lt;strong&gt;Conclusion:&lt;/strong&gt; Based on the prediction of anti-inflammatory bioactivity, five potential compounds were identified, namely cyclopentadecane, resveratrol, stilbenes, piceid, and hentriacontane. The five compounds bind to NFkB on the active site of the binding site with DNA, and this inhibition causes DNA to be unable to restrain NFkB transcription factors, and transcription does not occur. This proves that the active compound from the leaves of the plant&lt;em&gt; C. trifolia&lt;/em&gt; L has potential as an inhibitor of NF-κB compounds. Inhibition of 6 compounds on TNF at the TNF receptor proves that the active compound from the leaves of the plant &lt;em&gt;C. trifolia&lt;/em&gt; L has potential as a TNF-α inhibitor compound. The active ingredient Piceid exhibits predominant anti-inflammatory potential with lower binding energy and stronger interactions than other complexes.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue><work-type><style face="normal" font="default" size="100%">Research Article </style></work-type><accession-num><style face="normal" font="default" size="100%">23</style></accession-num><section><style face="normal" font="default" size="100%">407</style></section><auth-address><style face="normal" font="default" size="100%">&lt;p class=&quot;rtejustify&quot;&gt;&lt;strong&gt;Judya Sukmana&lt;sup&gt;1&lt;/sup&gt;, Widjiati&lt;sup&gt;2&lt;/sup&gt;, Siswandono&lt;sup&gt;2&lt;/sup&gt;, I Ketut Sudiana&lt;sup&gt;2&lt;/sup&gt;, Hari Basuki Notobroto&lt;sup&gt;2&lt;/sup&gt;, Iswinarno Doso Saputro&lt;sup&gt;2&lt;/sup&gt;, Yoes Prijatna Dachlan&lt;sup&gt;2&lt;/sup&gt;, Endang Joewarini&lt;sup&gt;2,*&lt;/sup&gt;&lt;/strong&gt;&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;1&lt;/sup&gt;Doctoral Program of Medical Science, Faculty of Medicine, Airlangga University, INDONESIA.&lt;/p&gt;

&lt;p class=&quot;rtejustify&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;Department of Doctoral Program, Faculty of Medicine, Airlangga University, INDONESIA.&lt;/p&gt;
</style></auth-address></record></records></xml>